19.3.2026 16:39:21 CET | Monsenso |
Selskabsmeddelelse
Selskabsmeddelelse nr. 02-2026
København, den 19. marts 2026
Denne meddelelses indeholder intern viden
I vores årsrapport for 2025 (note 2) skrev vi, at forhandlingerne omkring en større ordre var i sin afsluttende fase. Denne ordre er nu blevet underskrevet. Det ændrer ikke vores forventninger til omsætningen for 2026, men det reducerer de finansielle risici, vi tidligere har nævnt. Vi planlægger også at rejse yderligere kapital i andet kvartal af 2026.
Aftalen handler om at opsætte og levere Monsensos digitale sundhedsplatform til en international, privat udbyder af sundhedsydelser. Platformen skal benyttes til at indsamle patient-rapporterede data, støtte justering af medicin, give patienter information om deres behandling samt gøre kommunikationen mellem patienter og sundhedspersonale lettere og give en mere personligt tilpasset behandling i eget hjem.
”Potentialet for denne ordre er betydeligt. Den indeholder en indledende ordre på opsætning og konfiguration af platformen og vil generere løbende abonnementsindtægter fremover. Der er også et stort potentiale for at udvide til andre sygdomsområder, som kunden allerede arbejder med.” siger Thomas Lethenborg, CEO i Monsenso.
Yderligere oplysninger:
Monsenso
CEOThomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
BestyrelsesformandPeter Mørch EriksenE-mail: Petermorcheriksen@outlook.com
Certified Adviser:
HC Andersen CapitalBredgade 23, 1260 København K
Vedhæftninger
Download selskabsmeddelelse.pdf
19.3.2026 16:39:21 CET | Monsenso |
Company Announcement
Company Announcement no. 02-2026
Copenhagen, 2026.03.19
This message includes inside information
In our 2025 annual report (note 2), we mentioned that negotiation of an order was in the final stage. That order has now been signed. It does not change our revenue expectations for 2026, but it reduces the financial risks we mentioned. We also plan to raise additional capital in the second quarter of 2026.
As part of the agreement, Monsenso is configuring and delivering its digital health platform for an international, private healthcare provider. The platform will be used to collect patient-reported data, support medication adjustments, provide patients with information about their treatment and medication, facilitate communication between patients and healthcare providers, and deliver more personalised remote care.
“The potential of this agreement is significant. It includes an initial order to set up and configure the platform, and it will bring in recurring revenue in the future. There is also strong potential to expand into other disease areas already covered by the customer” says Thomas Lethenborg, CEO of Monsenso.
Further information:
Monsenso
CEOThomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Chairman of the boardPeter Mørch EriksenE-mail: Petermorcheriksen@outlook.com
Certified Adviser:
HC Andersen CapitalBredgade 23, 1260 København
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioral data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endeavors to deliver solutions that fit into the lives of patients and health care professionals. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
